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Abstract
Background Demand for total hip arthroplasty (THA) is
high and expected to continue to grow during the next
decade. Although much of this growth includes working-
aged patients, cost-effectiveness studies on THA have not
fully incorporated the productivity effects from surgery.
Questions/Purposes We asked: (1) What is the expected
effect of THA on patients’ employment and earnings? (2)
How does accounting for these effects influence the cost-
effectiveness of THA relative to nonsurgical treatment?
Methods Taking a societal perspective, we used a Mar-
kov model to assess the overall cost-effectiveness of THA
compared with nonsurgical treatment. We estimated direct
medical costs using Medicare claims data and indirect costs
(employment status and worker earnings) using regression
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models and nonparametric simulations. For direct costs, we
estimated average spending 1 year before and after surgery.
Spending estimates included physician and related ser-
vices, hospital inpatient and outpatient care, and postacute
care. For indirect costs, we estimated the relationship
between functional status and productivity, using data from
the National Health Interview Survey and regression
analysis. Using regression coefficients and patient survey
data, we ran a nonparametric simulation to estimate pro-
ductivity (probability of working multiplied by earnings if
working minus the value of missed work days) before and
after THA. We used the Australian Orthopaedic Associa-
tion National Joint Replacement Registry to obtain revision
rates because it contained osteoarthritis-specific THA
revision rates by age and gender, which were unavailable
in other registry reports. Other model assumptions were
extracted from a previously published cost-effectiveness
analysis that included a comprehensive literature review.
We incorporated all parameter estimates into Markov
models to assess THA effects on quality-adjusted life years
and lifetime costs. We conducted threshold and sensitivity
analyses on direct costs, indirect costs, and revision rates to
assess the robustness of our Markov model results.
Results Compared with nonsurgical treatments, THA
increased average annual productivity of patients by USD
9503 (95% CI, USD 1446–USD 17,812). We found that
THA increases average lifetime direct costs by USD 30,365,
which were offset by USD 63,314 in lifetime savings from
increased productivity. With net societal savings of USD
32,948 per patient, total lifetime societal savings were esti-
mated at almost USD 10 billion from more than 300,000
THAs performed in the United States each year.
Conclusions Using a Markov model approach, we show
that THA produces societal benefits that can offset the
costs of THA. When comparing THA with other nonsur-
gical treatments, policymakers should consider the long-
term benefits associated with increased productivity from
surgery.
Level of Evidence Level III, economic and decision
analysis.
Introduction
Total hip arthroplasty (THA) is a highly successful medical
intervention, having favorable long-term outcomes in terms
of improvement of physical functioning, survivorship, and
self-reported quality of life [2, 6, 24]. The increased
medical costs from surgery per quality-adjusted life year
(QALY) gained compares favorably with those of other
surgical procedures, such as lumbar discectomy, rotator
cuff repair, and ACL repair [18, 21, 22, 25, 26, 34]. Chang
et al. [9] showed that THA could be cost saving for some
patients compared with nonoperative treatment for end-
stage osteoarthritis (OA) after accounting for avoided costs
for nursing homes and other long-term care.
Owing in part to the aging population and expanded
indications, the number of THAs in the United States is
expected to increase substantially. Across all patients,
primary THA is projected to grow by 75% from 293,094 to
511,837 between 2010 and 2020 [20]. People younger than
65 years represent the fastest growing segment of patients
having THAs, accounting for 47% of all THAs performed
in 2012 compared with 34% in 1997 [15, 16]. One study
projected that more than 50% of THAs will be performed
in patients younger than 65 years by 2030 [19].
The current emphasis on reducing healthcare expendi-
tures may cause payers to limit utilization of THA by
implementing restrictive coverage or reimbursement poli-
cies. For example, in Oregon, a health plan for state
workers has placed enhanced cost-sharing requirements on
joint replacement, to reduce spending on the procedure.
The consequences of such policies will depend on the
societal benefits derived from THA. Because working-age
patients represent a large number of all patients having
THAs, potentially important indirect benefits from THA
relate to work status, such as maintaining employment,
reducing missed work days, and increasing workplace
productivity [28]. However, we are unaware of any studies
that account for work-related (indirect cost) benefits of
surgery.
The goal of our study was to determine the net societal
value of THA in the United States by estimating societal
costs and benefits. We build on the approach used by Dall
et al. [11] and Ruiz et al. [35], which links functional status
and economic outcomes to changes in patient outcomes
from surgery. The research addresses two questions: the
effects of surgery on employment and earnings and how
the inclusion of these factors influenced the measured cost-
effectiveness of THA relative to nonsurgical treatment.
Materials and Methods
We investigated the cost-effectiveness of THA compared
with nonoperative treatment for patients with OA of the hip
using a state-transition Markov decision model (Fig. 1).
Benefits were estimated from the societal perspective for a
patient cohort that had THAs. The cycle length was one
year and the model cycled until patient death. The primary
effectiveness outcome was expressed in QALYs. We used
Medicare payments adjusted to an all-payer population to
account for higher payment rates from private payers rel-
ative to Medicare. Costs and utilities were discounted at
3% per year. The model and analyses were performed
using a decision analysis software package (TreeAge Pro;
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TreeAge Software Inc, Williamstown, MA, USA) (Ap-
pendix 1. Supplemental material is available with the
online version of CORR1.)
Markov Model
Our decision tree consisted of two primary treatment
arms: THA and nonoperative treatment. There were eight
health states associated with the two treatment arms,
including six Markov health states (Fig. 1), one transi-
tional health state, and one absorbing state. In the Markov
process for THA (Fig. 1B), post-first revision THA rep-
resents failure of the primary THA. The model
differentiates between early and late failure of surgery and
revisions attributable to infection and asepsis. Post-second
THA revision is a transitional health state. A patient may
transition to a second THA revision after entering the
post-first THA revision state or stay in the post-first THA
revision state. Death was an absorbing state that could
occur at any point in the model based on the natural
mortality rates from the US Census Bureau’s life expec-
tancy tables [39]. If a patient transitions from a surgical
state, the probability of death is a combination of the
probability of natural mortality and surgical mortality,
which varied by age and gender. Patients who enter the
nonoperative treatment arm cannot cross over to the sur-
gical arm. While this assumption might not reflect clinical
reality, we imposed this requirement because we were
interested in the value of access to THA.
Model Assumptions
Indirect Costs
Our approach for estimating indirect costs was based on the
methods used by Dall et al. [11]. We used National Health
Interview Survey (NHIS) [7] data to generate regression
coefficients that described the statistical relationship
between physical functioning and economic outcomes. We
then applied regression coefficients to patient-reported
outcomes data to estimate the effects of surgery on the
likelihood of employment, earnings, and missed work days.
The relationship between earnings and functional status
was estimated using a two-stage Heckman selection model
to correct for potential bias created because earnings are
not observed for nonemployed individuals. We used a
probit model to predict employment and a linear regression
equation to predict earnings. The explanatory variables in
both models included age, race, marital status, family size,
education, and functional status indicators. Other sources
of income and the presence of other working household
members were included in the employment model. We
used multiple imputation techniques to correct for the
deflated standard errors that resulted from imputing per-
sonal income data in the NHIS [37].
Retrospective patient-reported outcomes data were
obtained at two large physician group practices. Patients
were asked to report on functional limitations using ques-
tions from the NHIS, which relate to ability to walk a
quarter mile, climb 10 steps, sit for 2 hours, stand for 2
Fig. 1A–B The Markov health state transition of both treatment arms
is shown. (A) For nonoperative treatment, a patient enters a
nonsurgery state and proceeds to end-stage hip OA, and then either
remains there or transitions to a more severe state with greater
functional impairment. (B) For surgical treatment (THA), a patient
either dies or survives the primary THA. After initial surgery, the
model assumes that individuals remain in a postprocedure state for 1
year (Initial Post-THA), which accounts for the costs and limitations
of treatment and recovery and any complications. After surviving the
initial (first year) post-THA state, patients either may enter the
successful THA state or undergo a revision and thus enter the post-
first THA early revision state. For patients entering successful THA
state, they may remain in this health state or have late failure, undergo
a revision, and thus enter the post-first THA late revision state. For
patients entering the post-first THA early or late revision, they may
remain in this health state or require a second revision, which was
considered as a transitional health state (not seen in the Markov
process).
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hours, stoop, carry a 10-pound bag, and push a large object.
Respondents were asked to report functional ability at the
time of the survey (followup) and to recall their function
just before THA (baseline). We obtained 77 usable
responses from patients (average age, 60 years; SD, 10.94
years) who generally received the survey 12 to 24 months
after THA (Appendix 1. Supplemental material is available
with the online version of CORR1).
We used a simulation-based approach to estimate the
change in productivity between baseline and followup. For
each iteration, we sampled 77 patients (with replacements)
from the patient-reported outcomes dataset. We then
applied patient responses to the functional assessment
questions to the Heckman model parameter estimates to
calculate the probability of employment and earnings
conditional on employment at baseline and followup for
each individual in the sample. We ran 1000 iterations of the
simulation. For each sample, we calculated the change in
mean productivity (equal to expected earnings) between
baseline and followup. We then calculated a mean change
in productivity across all 1000 samples and the 95% CI
using the distribution of mean change in productivity.
To generate results by age group and gender, we used
the functional status of the original sample of 77 responses
and predicted the probability of employment and earnings
by altering respondents’ age and gender. We used this
approach because employment and earnings are likely to
vary substantially by age and gender, and we did not have
enough observations to run the simulation by age-gender
subgroups. The findings on estimated changes in produc-
tivity by age and gender were incorporated in the Markov
decision model. Additional assumptions included: workers
missed an average of 40 work days to recover from THA
[12]; initial postsurgery year total costs were a combination
of medical costs and 50% of societal savings; and all
patients retired by the age of 75 years (ie, no indirect cost
benefits accrue after 74 years).
The study was approved by the institutional review
board in both practices. Detailed descriptions of patient-
reported outcome data, the estimated relationship between
functional limitations and indirect costs, and the indirect
cost assumptions are provided (Appendix 1. Supplemental
material is available with the online version of CORR1.)
Direct Costs
We used the Medicare Carrier, Home Health Agency,
Inpatient, Outpatient, and Skilled Nursing Facility 5%
sample Limited Data Sets [8] from 2009 to 2011 to esti-
mate direct costs for THAs and revision THAs. Patients
who received THA were identified using ICD-9 procedure
code 81.51 with a principal diagnosis of hip osteoarthritis
(ICD-9 diagnosis code 715.x5). We identified instances of
revision hip replacement using ICD-9 procedure code
81.53. The sample was limited to patients with Medicare
Part A and Part B coverage. We excluded patients who
died during the episode period or who had multiple primary
hip replacements.
Our direct cost estimate for surgical patients was com-
puted by averaging total payments 1 year after surgery. We
assumed that, if these patients had not received surgery,
their healthcare utilization in the subsequent year would
equal prior-year utilization. For revision, we computed
direct costs for 3 months following revision, and assumed
that direct costs for the remainder of the year resembled
those of patients who had primary hip replacement. Direct
costs include spending for services provided in hospitals
(inpatient and outpatient), home, physician offices, and
postacute care settings. Payments were inflated to 2011 US
dollars using the Medicare standardized amounts and
conversion factors of each setting. Medicare payments
were converted to all-payer payment rates using a con-
version factor. We assumed a successful primary or
revision THA reduced direct medical costs related to
symptomatic osteoarthritis by USD 590.
Utilities
We obtained utilities from Mota [29] for five of the health
states in our study: (1) nonsurgery; (2) end-stage hip OA;
(3) more severe OA; (4) successful post-THA; (5) post-first
revision THA.
These utilities, synthesized by Mota [29] in a literature
review, were based on studies researching individual
patient data of quality of life with the EuroQol five-di-
mensional (EQ-5D) questionnaire. We calculated the
utilities for the other two health states: (1) initial post-THA
and (2) post-second THA revision. The utility of initial
post-THA state was a combination of 25% of the pre-THA
utility and 75% of post-THA utility. The utility of post-
second THA revision was calculated based on the
assumption that post-second THA revision utility could
reach 90% of the utility for post-first THA revision
(Table 1).
Health State Transition and Transitional Probabilities
The transition probabilities for the nonsurgical treatment
arm were directly extracted from existing literature or
statistics. Specifically, the transition probability from end-
stage hip OA to more severe OA, and the probability of
death at each cycle were extracted from Mota [29] and the
US life tables [39], respectively.
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The perioperative revision mortality probabilities were
extracted from Mota [29], based on a literature review. Mota
synthesized findings of US-based THA revision studies that
involved large US patient databases—US Medicare claims
and National Inpatient Sample, and risk adjustment by
patient characteristics. For the perioperative THA mortality,
we conducted a systematic literature review to obtain
mortality rates for more granular age categories than the ones
presented by Mota [29]. We used the risk-adjusted mortality
rates reported by Memtsoudis et al. [27], which had the most
granular age categorization based on our literature review
(Table 1). Revision rates were obtained from the Australian
Orthopaedic Association National Joint Replacement Reg-
istry [1] (Table 1). We used the Australian joint replacement
Table 1. Transition probabilities, utilities, and medical costs in the Markov model for THA
Parameter Value Source
Mortality
Natural death Varies by age and gender US Census Bureau Life Expectancy Table [39]
Perioperative THA death Varies by age and gender Memtsoudis et al. [27]




Early aseptic first revision Varies by age and gender Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Late aseptic first revision Varies by age and gender Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Early aseptic second revision 0.0583 Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Late aseptic second revision 0.022 Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Early infection first revision Varies by age and gender Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Late infection first revision Varies by age and gender Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Early infection second revision 0.017 Australian Orthopaedic Association National Joint Replacement
Registry [1]; Parvizi et al. [32]
Late infection second revision 0.006 Australian Orthopaedic Association National Joint Replacement
Registry [1]; Lie et al. [23]
Transitional probability of nonoperative treatment to more severe OA
More severe OA 0.041 Mota [29]
Utility
End-stage hip OA Varies by gender Value for males: 0.52; for females: 0.47; Mota [29]
Nonsurgery Varies by gender Value for males: 0.52; for females: 0.47; Mota [29]
More severe OA 0.28 Mota [29]
Initial post-THA 0.74 Mota [29]; current authors’ calculation
Successful post-THA Varies by gender Values for males: 0.83; for females: 0.8; Mota [29]
Post-first revision THA (early
and late)
0.64 Mota [29]
Post-second THA revision 0.58 Mota [29]; current authors’ calculation
Annual direct medical costs
End-stage OA/nonsurgery/more
severe OA
USD 12,815 Current authors’ calculation
Initial post-THA USD 38,965 Current authors’ calculation
Successful THA USD 12,225 Base value: medical cost of end-stage OA USD 590; current authors’
calculation
First aseptic revision THA (early
and late)
USD 57,141 Current authors’ calculation
First infection revision THA
(early and late)
USD 95,763 Current authors’ calculation
OA = osteoarthritis.
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registry because it was the only registry that contained OA-
specific THA revision rates by age and gender. In addition to
the Australian registry, we also searched the Swedish, Nor-
wegian, and British registries. The US registry was launched
in 2012, so it does not contain the late revision rates that we
need for our model.
Early revision rates were modeled as revision surgery in
the year after index THA, whereas late failure was modeled
as revision surgery in subsequent years. We also differen-
tiated between a patient’s first and subsequent revisions,
and aseptic and infection revisions. The first-time aseptic
revision rate was 6.69 times the first-time infection revision
rate [1] and the second aseptic revision rate was 3.4 times
the second infection revision rate [32]. We estimated the
first revision rate by age weighted on the gender distribu-
tion of all patients who had THA in 2011.
Sensitivity Analysis
We conducted threshold analyses to identify the value of
key parameters where net savings equal zero. In addition,
we performed Monte Carlo analysis to evaluate: (1) the
effect of uncertainty in the model assumptions regarding
indirect cost benefits using probabilistic sensitivity analysis
and (2) the effect of individual patient variability in age
and gender using microsimulation.
Results
Expected Effect of THA on Patients’ Employment and
Earnings
We estimated that THA increases the overall likelihood of
employment by 18% (95% CI, 12%-23%). Our simulation
found no difference in average annual earnings among
workers who underwent THA relative to those who pursued
nonsurgical management (mean change in earnings, USD
5073; 95% CI, USD 3188 to USD 13,387). Overall, we
estimated that the average annual change in productivity,
which reflected changes in the likelihood of employment and
earnings, increased by USD 9503 for patients undergoing
THA (95% CI, USD 1446–USD 17,812). We also estimated
that THA reduces missed work days in a year by 36 days, from
50 to 14 missed work days (95% CI, 12–75 days). This esti-
mate of missed work days did not incorporate missed work
days to recover from THA, which we assumed was 40 days.
We estimated the effects of THA by age and gender
(Table 2). The results showed changes in estimated annual
earnings, value of missed work, and productivity for
patients undergoing THA compared with nonoperative
treatment. The expected effects of THA on productivity
ranged from USD 15,830 (males 40 to 49 years old) to
USD 1917 (females 70 to 74 years old). The wide variation
by age and, to a lesser extent, gender largely reflected
differences in labor force participation rates (and likelihood
of being employed) in these categories.
Cost-effectiveness of THA Relative to Nonsurgical
Treatment
Using our Markov model, we estimated that mean lifetime
direct cost for THA per patient was USD 30,365 higher
than nonoperative treatment (Table 3). The incremental
direct costs associated with surgery were offset by USD
63,314 in indirect cost savings for a net societal savings of
USD 32,948. Therefore, THA was a dominant treatment
strategy relative to nonoperative treatment because it
resulted in overall cost savings with 5.5 more QALYs.
Although the results showed net societal benefits from
THA in the entire cohort, direct medical costs began to
exceed indirect cost savings after patients were 64 years
old. THA was cost-effective for all age groups at tradi-
tional willingness-to-pay thresholds, with the highest
incremental cost per QALY gained at USD 10,748 for
patients 75 years old or older.
The results showed that younger patients receiving THA
accrued substantially higher lifetime savings because of the
longer length of time in the workforce. The difference in
indirect cost savings between the youngest group (40–49
years old) and patients between 70 and 74 years old was











40–49 years 14,486 1344 15,830
50–59 years 15,408 991 16,399
60–64 years 14,021 397 14,419
65–69 years 9336 79 9415
70–74 years 4283 –9 4274
C75 years* 0 0 0
Female
40–49 years 11,781 761 12,542
50–59 years 12,352 559 12,911
60–64 years 9930 167 10,097
65–69 years 5477 6 5470
70–74 years 1927 10 1917
C 75 years* 0 0 0
Values represent the 1-year difference in earnings or value of missed
work between THA and nonoperative treatment options; *we
assumed individuals retire by 75 years and therefore surgery results in
no change in earnings, missed work days, or total productivity.
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USD 213,074 over a lifetime (Table 3). The average net
societal savings for patients younger than 65 years was
USD 97,892, while no societal savings were obtained for
patients 65 years and older.
Sensitivity Analyses
We performed a threshold analysis to estimate the sensi-
tivity of societal savings from THA to key model
assumptions for patients 55 and 60 years old (Table 4). The
results were robust to many of the model assumptions; we
observed societal savings even after decreasing or
increasing the base case assumptions (Table 4) by a factor
of 10. With respect to productivity, the breakeven points
for a female (male) 55 and 60 years old were 26% (20%)
and 41% (28%) of base case assumptions (Table 1) (Ap-
pendix Table 3. Supplemental material is available with
the online version of CORR1).
We used a Monte Carlo simulation to perform a prob-
abilistic sensitivity analysis to assess the effect of
parameter uncertainty in the indirect cost benefits. The
mean lifetime cost for THA was USD 142,975 (95% CI,
USD 141,960 –USD 143,990) and the mean cost of non-
operative treatment was USD 177,875 (95% CI, USD
177,700–USD 178,051) for a mean net benefit of USD
34,900 (95% CI, USD 33,880–USD 35,920). For a typical
patient in the US healthcare system, THA was the cost-
saving strategy in more than 95% of trials (Fig. 2). The
ellipse in that figure captured the 95% CI for the difference
between the means of each strategy.
Discussion
Demand for THA among working-age patients has con-
tributed to the growth in surgeries during the last decade.
According to the Healthcare Cost and Utilization Project
Table 3. Summary of the lifetime costs and savings from THA by age
Age group Incremental direct cost
(A) (in USD)
Incremental indirect cost
savings (B) (in USD)
Net societal savings
(C) (in USD)
QALY gained (D) ICER (C/D)
\ 65 years 28,067 125,958 97,892 7.0 Dominant
40–49 years 28,905 218,738 189,833 8.3 Dominant
50–59 years 28,128 136,023 107,894 7.1 Dominant
60–64 years 27,564 65,659 38,095 6.0 Dominant
C 65 years 32,323 10,052 22,271 4.2 5255
65–69 years 30,147 28,157 1990 5.4 371
70–74 years 30,162 5664 24,497 4.4 5618
C 75 years 35,468 0 35,468 3.3 10,748
All 30,365 63,314 32,948 5.5 Dominant
ICER = incremental cost-effectiveness ratio; Net societal savings = Column B minus Column A; QALY = quality adjusted life year; weights by
gender in age groups were calculated using 2011 National Inpatient Sample data.
Table 4. Base case and threshold values for zero net societal savings
Parameter Base case (male, female) Age 55 years Age 60 years
Threshold Threshold
First aseptic revision rate (early) 1.31%, 1.13% Robust Robust
First aseptic revision rate (late) 0.61%, 0.63% Robust Robust
First infection revision rate (early) 0.20%, 0.17% Robust Robust
First infection revision rate (late) 0.09% Robust Robust
End-stage osteoarthritis [1] USD 12,815 Robust Robust




Productivity Varies by age and gender 26% of base (female)
20% of base (male)
41% of base (female)
28% of base (male)
Parameters are considered robust if net savings remain at 10 times the value of the base case; direct cost of end-stage osteoarthritis includes all
medical costs, not just those associated with treatment of osteoarthritis.
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statistics based on the Nationwide Inpatient Sample [16],
the number of THAs performed on patients 18 to 64 years
old has increased by 91% from 100,376 to 192,105
between 2003 and 2013. The potential benefits of THA
include greater work participation and earnings and fewer
missed work days. The societal effect of THA depends on
these indirect cost benefits from surgery. To our knowl-
edge, our study is the first to incorporate these potential
indirect cost benefits of surgery in a model on the cost-
effectiveness of THA. Because patients are receiving THA
at younger ages, the inclusion of employment and earnings
benefits results in a more accurate assessment of the true
societal effects of surgery. Our study shows that after
accounting for productivity gains from THA, THA is
superior to nonsurgical procedures for patients with hip OA
in terms of societal value. On average, THA results in net
societal savings of USD 32,948 per patient and adds 5.5
QALYs over a patient’s lifespan.
The current study has several limitations. First, we
inferred the effects of THA on employment, earnings, and
missed work days by using the estimated relationship
between functional limitations and economic outcomes for
a sample of NHIS respondents and linking these estimates
to patient-reported outcome for a sample that underwent
THA. Although this technique followed prior research
[11, 35], the method is based on the assumption that
treatments only affect productivity through their impact on
functionality. This approach takes the perspective of an
average working patient and, thus, may not be applicable to
patients in a specific occupation.
Second, to estimate the post-THA productivity, the
patient-reported outcome functionality data were collected
retrospectively from patients up to 2 years after THA. Our
sample was small and response rates were low (30%),
which raises concerns regarding the generalizability of the
findings. In addition, our retrospective approach introduces
the possibility of recall bias regarding functional limita-
tions before surgery. To assess potential recall bias, we
compared baseline functional status values with published
values [3, 14, 17, 31, 33]. Using a functional limitations
index scale (ranging from 0 to 100, with higher values
indicating greater function impairment), we found an
average index score of 54 before THA based on our col-
lected patient-reported outcome data. Our sample had
similar preoperative function compared with those
observed in previous studies, which ranged from 55 to 63
(of 100) in prospective studies using the WOMAC func-
tional score [3, 14, 17, 31, 33]. Third, we assumed that the
productivity of the nonsurgical group would be maintained
at the presurgery values. Fourth, we used summary statis-
tics from the Australian Joint Replacement Registry [1] to
estimate the early and late revision rates. The revision rates
from the Australian Orthopaedic Association National Joint
Registry may serve as only a limited proxy for the US
revision rates to the extent that patient demographic and
clinical characteristics and joint replacement technologies
differ between the two countries. Fifth, the economic and
societal benefits of THA might be undervalued because we
do not incorporate the value of nonpaid work, such as child
care. Finally, our study focuses on the societal values of
typical THAs performed in the inpatient setting.
In this study, we explored the effects of THA on
employment, earnings, and missed work days and then
assessed how these effects affect the measured cost-effec-
tiveness of THA. We estimated increases in the likelihood
of being employed (from 39% to 57%) and annual pro-
ductivity (USD 9503). The study findings showed the
importance of work-related benefits from THA. Concep-
tually, the potential effects of continued end-stage OA of
the hip versus THA on workplace productivity seem clear.
People with hip pain and associated functional limitations
may be unable to work or may need to work a part-time or
more limited schedule. Among people with end-stage OA
who are able to maintain full-time employment, the effects
on productivity have the potential to negatively influence
their earnings. Empirical evidence on the effect of end-
stage OA and THA on employment is limited, but gener-
ally supportive of the view that THA allows patients to
maintain employment [4]. Numerous studies have shown
that the majority of patients having THA return to work
after the surgery [5, 10, 13, 30, 38]. For those returning to
work, most do not encounter functional limitations in their
ability to fully engage in work activities [30, 36]. Two
Fig. 2 The Y-axis and X-axis values of each dot correspond to the
incremental cost and incremental effectiveness (THA vs nonsurgery)
for a sampling of 1000 average American patients (mean age, 66
years; sex, 42% women). The dispersion illustrates the effect of
uncertainty of the indirect cost parameters, which follow logistic and
lognormal distribution for male and female patients respectively.
QALYs = quality adjusted life years
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studies found that some patients who are out of work
before surgery regained employment after THA [4, 28].
After incorporating the effects of THA on productivity,
we showed a positive societal rate of return on healthcare
spending for THA. We estimated that THA results in
incremental direct costs of USD 30,365, which were offset
by USD 63,314 in lifetime savings from increased pro-
ductivity, for an average net societal savings of USD
32,948. We found that the estimated lifetime societal net
benefit is comparable to that estimated for TKA (USD
18,930; USD 39,565 indirect cost benefits and USD 20,635
direct medical costs) [35].
Societal savings from THA were greater for younger
patients because of their higher remaining years in the
workforce, with a breakeven point at age 65 years. Find-
ings on overall cost savings of THA were robust to model
assumptions for patients younger than 60 years. For
patients 65 years or older, the existence of societal savings
was sensitive to revision rates, medical costs of primary
and aseptic revision THAs, and indirect cost savings.
Nevertheless, the procedure is highly cost-effective
regardless of age when using standard thresholds of
incremental cost per QALY, findings consistent with those
of prior studies [9, 29]. We estimated a total life societal
savings of almost USD 10 billion from the more than
300,000 THAs performed in the United States each year.
Our study concludes that THA produces net societal sav-
ings because of its effect on younger patients’ work status
and earnings. Policy makers and payers should consider the
indirect cost benefits of THA when assessing policies to
control healthcare spending and improve quality. Given the
positive return to society from spending on THA, as shown
in our model results, policy proposals that discourage
decisions to choose THA may be counterproductive.
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